Compounds and compositions as protein kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9593099-B2
Application number	US-201614994710-A
Country	US
Kind code	B2
Filing date	Jan 13, 2016
Priority date	Aug 28, 2009
Publication date	Mar 14, 2017
Grant date	Mar 14, 2017

Abstract

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

First claim

We claim:

1. A compound of the formula:

(methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate), or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.

Assignees

• Array Biopharma Inc

Inventors

• Huang Shenlin
• Jin Xianming
• Liu Zuosheng
• Poon Daniel
• TELLEW John
• Wan Yongqin
• Wang Xing
• Xie Yongping

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P1/08

  for nausea, cinetosis or vertigo; Antiemetics · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title